A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of 12-week Treatment With GW590735X (20ug) or GW501516X (10mg) Relative to Placebo on Measures of Adiposity and Inflammation in Overweight and Obese Subjects.
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2012
At a glance
- Drugs GW 501516; GW 590735
- Indications Obesity
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 09 Nov 2007 Status changed from in progress to completed
- 31 Oct 2006 New trial record.